
BIOLASE (BIOL) Stock Forecast & Price Target
BIOLASE (BIOL) Analyst Ratings
Bulls say
Biolase Inc. projects an annual revenue growth of approximately 6-8% for 2024, targeting revenue between $52-53 million and positive adjusted EBITDA for the year. The company is leveraging its technological leadership to enhance commercial execution through established market development programs, which may foster consistent sales growth. Additionally, potential gross margin improvements could arise from increased sales volume, pricing strategies, reduced production costs, and efficient manufacturing processes.
Bears say
Biolase Inc. has lowered its 2024 revenue growth expectations from an anticipated 6-8% to flat, reflecting a significant downturn in market conditions and leading to a revised revenue estimate of $47.9 million, down from $52.4 million. The majority of the company’s revenue is derived from the United States, a market currently facing challenges that may contribute to this negative outlook. Additionally, regulatory uncertainties pose a risk that could delay or prevent the approval of new products, further impacting the company’s growth potential.
This aggregate rating is based on analysts' research of BIOLASE and is not a guaranteed prediction by Public.com or investment advice.
BIOLASE (BIOL) Analyst Forecast & Price Prediction
Start investing in BIOLASE (BIOL)
Order type
Buy in
Order amount
Est. shares
0 shares